Vanguard Group Inc. Sells 3,842,394 Shares of Ironwood Pharmaceuticals, Inc. $IRWD

Key Points

• Vanguard Group Inc. reduced its stake in Ironwood Pharmaceuticals by 19.7%, selling 3,842,394 shares and owning approximately 9.70% of the company post-sale.
• Ironwood Pharmaceuticals has recently received a rating upgrade from "hold" to "strong buy", with one analyst predicting a 0.1 earnings per share for the current fiscal year.
• The company reported earnings of $0.14 per share for the quarter, outperforming estimates, and had a revenue of $85.24 million against expectations of $62.02 million.

Vanguard Group Inc. reduced its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 19.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,696,161 shares of the biotechnology company's stock after selling 3,842,394 shares during the period. Vanguard Group Inc. owned approximately 9.70% of Ironwood Pharmaceuticals worth $23,073,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in Ironwood Pharmaceuticals during the 4th quarter valued at $36,000. Envestnet Asset Management Inc. bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth $50,000. Boothbay Fund Management LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth $57,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth $59,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth $68,000.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD remained flat at $1.32 during midday trading on Monday. The stock had a trading volume of 548,103 shares, compared to its average volume of 1,456,046. The stock's 50 day moving average is $0.89 and its 200-day moving average is $1.01. Ironwood Pharmaceuticals, Inc. has a 12-month low of $0.53 and a 12-month high of $5.21. The firm has a market cap of $214.41 million, a price-to-earnings ratio of -26.39 and a beta of 0.32.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.16. The company had revenue of $85.24 million for the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $4.94.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.